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ABSTRACT 
Objective: To determine the frequency of extended-spectrum beta lactamase producing Enterobacteriaceae(ESBL) and other 
antibioticsresistant bacteria in urinary tract isolates. 
Study Design: prospective and experimental study. 
Methodology: Place and duration of study :YalgadoOuedraogo University Hospital Center, Charles De Gaulle Pediatric 
Hospital Center, Saint Camille Hospital and National Public Health Laboratory,  Ouagadougou, from November 2014 to  
October 2015. 
AllEnterobacteriaceaestrains isolated from urinary samples of patients were identifiedusing API 20E chemical gallery 
(BioMerieux, France). All strains were subjected to an array of 14 antibiotics to study their drug susceptibility by using Kirby-
Baeurdisk diffusion method. Detection of ESBL was carried out by double disk diffusion technique. Statistical analysis was 
performed by Microsoft Excel and Anova one-way GrapPad Prism version 5.01. Chi-square (χ2) test was used to determine 
significance. A p˂ 0.05was considered to be statistically significant. 
Results: A total of 324 isolates of Enterobacteriaceae were identified during the study period, including211(65%) E. coli, 75 
(23%)Klebsiella spp., 18 (6%) Enterobacter spp., 11 (3%)Proteus spp., 5 (2%) Citrobacter spp., Serratia spp. 3 (1%).All the clinical 
isolates were susceptible to imipenem. Resistance to amikacinwas 14% (45/324); gentamicin 54% (175/324); tobramycin 58% 
(187/324); nalidixic acid 72% (234/324),ciprofloxacin 63% (204/324) and to cotrimoxazole 83% (269/324).The overall rate of the 
EBSL producing strains was 35% (114/324). Their susceptibility to antibiotics was (imipenem,amikacin, cefoxitin and 
fosfomycin) 100% (114/114), 93% (106/114), 74% (84/114) and 84% (96/114) respectively. ESBL positivity within individual 
organism group was highest inEscherichia coli 64% (73/324) followed byKlebsiellaspp. 28% (32/324), Enterobacterspp. 3% (4/324), 
Proteus spp. and Citrobacterspp. 2% (2/324).  
Conclusion: The results showeda high frequency of ESBL producing Enterobacteriaceae, especially Escherichia coli and 
Klebsiellaspp. The data points to theneed of routine detection and surveillance of ESBL producing bacteria in Burkina Faso. 
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SENSIBILITE DES ENTEROBACTERIES PRODUCTRICES DE BETA-LACTAMASESA SPECTRE ELARGI ISOLEES DES 
INFECTIONS URINAIRES, OUAGADOUGOU, BURKINA FASO 
Résumé 
Objectif : Déterminer la fréquence des entérobactéries productrices de bêta-lactamases à spectre élargi(BLSE)et la résistance aux 
autresantibiotiques utilisésle traitement des infections urinaires. 
Type de l’étude : Etude prospective et expérimentale 
Méthodologie : Lieu et période : Centre Hospitalier Universitaire YalgadoOuedraogo, Centre Hospitalier 
UniversitairePédiatrique Charles De Gaulle, Hôpital Saint Camille et Laboratoire National de Santé Publique,  Ouagadougou, 
de Novembre 2014 à  Octobre 2015. 
Toutes les entérobactéries isolées des urines de patients et identifiées sur galerie API 20E (BioMerieux, France). Quatorze (14) 
antibiotiques ont été utilisés pour tester la sensibilité des souches cliniques par la méthode de diffusion des disques selon 
Kirby-Bauer. La détection des souches productrices de BLSE a été faite en utilisant la technique de test à double synergie. Le 
logiciel Excel et Anova one-wayGrapPadPrism version 5.01ont été utilisés pour l’analyse statistique et le test de χ2au seuil de p 
< 0.05 était considéré statistiquement significatif. 
Résultats: Un total de 324 souches d’Enterobacteriaceae ont été collectées durant la période d’étude composées de 211 (65%) 
souches de E. coli,  75 (23%)Klebsiellaspp. ,18 (6%) Enterobacterspp., 11 (3%)  Proteusspp.,5 (2%)Citrobacterspp. , 3 (1%)  
Serratiaspp. 
Toutes les souches d’entérobactéries étaient sensibles àl’imipenème. La résistanceà  l’amikacineétait de  14%(45/324); la 
gentamicine 54% (175/324); la tobramycine 58% (187/324); l’acidenalidixique 72% (234/324),  la ciprofloxacine 63% (204/324) et  le 
cotrimoxazole 83% (269/324). La fréquence des souches productrices de BLSE était  35% (114/324). Leurs taux de résistance aux 
antibiotiques étaient de 100% (114/114), 93% (106/114), 74% (84/114) et 84% (96/114) respectivement àl’imipeneme, à l’amikacine, 
à la cefoxitineetà la fosfomycine.Lafréquence des souches productrices de  BLSE par espèceétaitélevée chezEscherichia coli 64% 
(73/324) suivie deKlebsiellaspp. 28% (32/324), Enterobacterspp. 3% (4/324), Proteusspp.etCitrobacterspp. 2% (2/324).  
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Conclusion:35% des souches cliniques étaient productrices de BLSE. Une fréquenceélevée des entérobactéries productrices de 
BLSE aétéobservée chez l’espèceE. coli et  Klebsiellaspp parmi les souches cliniques testées. Les résultats montrent une nécessité 
de mettre en place un système de surveillance des souches productrices de BLSE au Burkina Faso. 
Mots clés: Sensibilité aux antibiotiques, Enterobacteriaceae, Urine, Burkina Faso 
 
INTRODUCTION 
Urinary tract infections(UTI) is one of the most 
common infectious diseases ranking next to upper 
respiratory tract infection, it is an important cause of 
morbidity and mortality in human. Infected urine, 
renal calculi, obstructive uropathy, vesico ureteral 
reflux and avoiding disorders can lead to urinary 
stasis and may predispose to the development of UTIs 
and complications [1].It has been estimated that 
nearly 10% of the human population will experience 
an UTI during the life time [2, 3, 4]. Resistance to 
commonly-prescribed antibiotics is an expanding 
global problem and has been observed in both 
developed and developing countries[5, 6, 7, 8]. 
Enterobacteriaceae are the major causative organisms of 
UTIs and are responsible for more than 81% of UTIs 
cases. Escherichia coli is the most prevalent causative 
organisms of UTIsand is solely responsible for more 
than 69% of the infections [1,9,10]. 
Bacterial resistance to antibiotics has emerged even to 
newer, more-potent antibacterial agents [11]. A 
number of epidemics have recently occurred caused 
by multiple resistant organisms [12, 13]. 
In Burkina Faso, UTIs due to Enterobactriaceae are 
common and represent a frequent cause of morbidity 
in outpatients as well as a frequent cause of 
nosocomial infections in many hospitals. Most 
infections are treated on an empirical basis. Clinical 
experience has indicated the presence of numerous 
cases of infection resistant to conventional antibiotics 
therapy. Microbial resistance rates to commonly 
prescribed antibiotics have increased recently. 
Updated knowledge of urinary tract infections 
Enterobacteriaceae, the frequency of ESBL strains and 
the susceptibility patterns to other antibiotics is 
important for the proper selection and use of 
antibiotic and for the development of an appropriate 
prescribing policy. The aim of this study was to 
determine the frequency of ESBL strains and the 
susceptibility patterns of other antibioticresistant 
bacteria of clinical importance responsible for urinary 
tract infections in Ouagadougou, Burkina Faso. 
 
 
Materiel and methods 
Study population and settings 
This study was an experimental study ofbeta-lactam 
and other antibiotics resistance expression 
ofEnterobacteriaceae.The socio demographic data 
andEnterobacteriaceae strains were obtainedfrom 
patients who came for an etiological diagnosis for 
bacterial infectionfrom November 2014 to October 
2015. 
The Enterobacteriaceaestrains were obtained from 
thefollowing 3 health centers in Ouagadougou: 
YalgadoOuedraogo University Hospital (CHU-YO), 




Gaulle Pediatric University Hospital (CHUP-CDG), 
the referral public pediatric hospital with 120 bedsand  
 
Saint Camille Hospital (HOSCO), the confessional 
hospital. 
All Enterobacteriaceae strains collected at these 3 
different sites were transported to the LNSP 
Bacteriology-Virology Laboratoryfor Enterobacteriaceae 
investigation. Strains identification was performed 
using API 20 E gallery (Biomérieux, Marcy- L’étoile, 
France) after 24 hours incubation at 37 ° C. 
The isolated and identified strains were seeded on 
Mueller-Hinton (MH) agar for 18 to 24 hours in order 
to have young and pure colonies.All clinical isolates 
were stored at -30°C for future investigations at 
Institut Pasteur de Côte d’Ivoire (IPCI).  
Antibiotic Susceptibility Testing 
All isolates were tested for susceptibility to 14 
different antimicrobial agents using the disk diffusion 
method on Mueller-Hinton agar (BioRad, France) 
following the European Committee on Antimicrobial 
Susceptibility Instructions (EUCAST) guidelines (CA-
SFM/EUCAST, 2016). E. coli ATCC 25922 and ATCC 
35218 were used as a control. The antimicrobial disks 
(Bio-Rad, France) used were:gentamicin (15 µg), 
amikacin (30 µg), tobramycin(15µg), Amoxicillin 
(25µg), amoxicillin + clavulanic acid (20µg), cefepim 
(30µg), cefotaxim (30µg), ceftriaxon (30µg), cefoxitin 
(30µg), imipenem (10µg), ciprofloxacin (5µg), 
cotrimoxazole (1.25 / 23.75µg), nalidixic acid (30ug) 
and fosfomycin (50µg). 
 
ESBL strains screening  
The double-disk synergy tests (DDST) to detect ESBL-
producing isolates was performed on Mueller-Hinton 
agar, placingcefepim, cefotaxim, and ceftriaxone discs 
around the amoxicillin + clavulanic acid diskat a 
distance of 3cm from the center to center, according to 
theEuropean Committee on Antimicrobial 
Susceptibility Instructions (EUCAST) guidelines (CA-
SFM/EUCAST, 2016) (14). 
 
Determination of multiple antibiotic resistance 
index 
Multiple antibiotic resistance index (MAR) was 
determined using the formula MAR=x/y, where x was 
the number of antibiotics to which test isolate 
displayed resistance and y is the total number of 
antibiotics to which the test organism has been 
evaluated[15]. 
Statistical analysis 
Statistical analysis was performed with Excel and 
Anova one-way GrapPad Prism version 5.01. Chi-
square (χ2) test was used to calculate probabilities 
and determine significance. A p-value of less than 





Characteristic of the study population and 
distribution of strains 
(162 men and 162 women) in 3 hospital centers in 
Ouagadougou, Burkina Faso.The mean age of these 




FIGURE 1: DISTRIBUTION OF DIFFERENT SPECIES 
BELONGING TOENTEROBACTERIACEAE
ISOLATED DURING THE STUDY
 
This figure showed that urine samples are the samples 
which predominant 65% (211)
 
Out of 324 Enterobacteriaceae isolates, 211(65%)were 
coli, 75 (23%) Klebsiella spp., 18 (6%) Enterobacter
11 (3%)Proteus spp., 5 (2%) Citrobacter
spp. 3 (1%)as shown inFigure 1. 
 
 
FIGURE 2: ESBL PRODUCING ISOLATES WITHIN 
INDIVIDUAL STRAINS DIVIDED BY TOTAL 
ISOLATES OF THAT ORGANISM REPRESENT 




The most frequent urinary Enterobacteriaceae
were E. coIi, Klebsiella species, and Enterobacter species. 
Other urinary tract bacteria were isolated in
few number. These included Citrobacter 















A total of 324 clinical isolates belonging to 


































>60 years 84 30 
 
*p = 0.5321, no significant statistically
 
 
TABLE 2:RESISTANCE RATE OF44 ESBL



















Antibiotics susceptibility test 
The antibiotic resistance profile of the urinary tract 
isolates is shown in figure 3. All the strains isolated
showed high resistance to amoxicillin 88% (286/324), 
amoxicillin/clavulanicacid 38% (124/324), gentamicin 
54% (175/324), tobramycin 58% (187/324), 
ciprofloxacin 63% (204/324), nalidixic acid 72% 
(234/324) and to cotrimoxazole 83% (269/324). 
However, there was low resistance toamikacin 14% 
(45/324)and fosfomycin 18% (57/324) (Figure 3).  All 
strains were susceptible toimipenem.  
and Klebsiella pneumonia showed high rate of resistance 
to gentamicin, tobramycin, amoxicillin and all the 3rd 













































S = Sensitive, R = Resistance 
FIGURE3: RESULTS OF OVERALL RESISTANCE AND SENSITIVITY OF ALL 
ANTIBIOTICS. AMIKACIN, IMIPENEM AND FOSFOMYCIN SHOWED THE BEST SUSCEPTIBILITY RATE.
 
Occurrence of ESBL-producing Enterobacteriaceae
The overall rate of ESBL-producing Enterobacteriaceae
in UTIs in both male and female patients was found 
to be 35% (114/324). The frequency of ESBL strains 
within individual organism group was 
(73/324),Klebsiellaspp. 28% (32/324), Enterobacter
3% (4/324), Proteus spp.andCitrobacter 
(2/324)as shown in Figure 2.E. 
producingESBL were higher than those of the other 
species.  
 
Considering the clinical isolates origin, ESBL strains 
rate was 24 % (78/324) at CHU-YO, 4% (13/324) at 
Saint Camille Hospital (HOSCO) and 7 % (23/324) at 
CHUP-CDG.The mean age of patients with ESBL 
producing organisms was 32.38 years compared to 
27.66 years for patients with non-ESBL strains. ESBL 
production among various age groups ranged from 
32% to 42%. However, there was no statistically 
significant difference between the age groups (Table 
1) with respect to ESBL production (p 
producing strains showed high susceptibility 
rateswith imipenem 100% (114/114), amikacin 93% 
(106/114), cefoxitin 74% (84/114) and fosfomycin 84% 
(96/114) (Table 2) 
 
DISCUSSION 
In this study, we investigated the frequency of ESBL 
production by Enterobacteriaceae isolates in three 
hospitals in Ouagadougou, Burkina Faso.
A total of 324 clinical isolates belonging to 
Enterobacteriaceae family were obtained from urine 
samples from these3 centers in Ouagadougou, 
Burkina Faso from November 2014 to October 2015. 
These bacteriawere isolated from 162 females and 162 
males. The patients mean age was33.7 ± 2 years and 
the sex ratio 1.7. 
UTIs are the most common nosocomial infections, 
comprising about 35% of such occurrences in both 
hospitals and nursing homes [16]. 
More than 95% of UTIs are caused by a single 
bacterial specie and Escherichiacoli is by far the most 








































The spectrum of strains isolated from urinary samples 
in this study is not different from those
literature.  
In this study, all of the 324 Enterobacteriaceae
Escherichia coli predominated followed by 
spp. and Enterobacterspp.Citrobacter
spp. were less significant. 
In several others studies in Burkina Faso,Sudan, 
India,Pakistanand Ivory Coast[18,19,
authorsreported that Escherichiacoli 
common isolate followed by 
Enterobacterspp. and Proteus spp. 
 
E. coli remains an essential bacterium in urinary tract 
infections. Wilson and Gaido[28]also 
coliis the major bacterial etiology of urinary tract 
infections. This corroborates the high frequency of 
coli isolates reported in our study. 
The antibiotic susceptibility tests revealed in our 
study high levels of resistance to certain molecules 
used in common practice.Our study also revealed that 
88% (286/324)of isolates were resistance to 
amoxicillin, which may be due to the frequent and 
possiblemisuse of this antibiotic. The resistance rate to 
amoxicillin + clavulanicacid was38% (124/324).In 
contrast with the report of Adonis
Ivory Coast who obtained a resistance rate of 68% to 
amoxicillin + clavulanic acid. 
The high levelresistance of the Enterobacteriaceae
and 4th generation cephalosporin antibiotics 
also observed (cefepim showed 58%, cefotaxim 59% 
and ceftriaxon 63%). 
The most active molecule among the 
aminoglycosideantibiotic family was amikacinand the 
resistance rate of strain was 14%;BonniCisse et 
did observe the same trend in  Ivory Coast.  Other 
aminoglycoside antibiotics tested were gentamicin 
and tobramicinwith resistance rates of 54% and 
58%respectively.Leski et al.[29]in Sierra Leone 
however reported ahigh percentage (73%) resistance 
to gentamicin. 
Furthermore, the clinical strains s






















was also the most 
Klebsiellaspp., 














resistance rates were 63% (204/324) and 72% 
(234/324)respectively.Results of our study is similar 
to that of Guessennd et al. [25] conducted from 2005 
to 2006 in which the resistancerateto quinolones was 
71% to ciprofloxacin and 77% tonalidixic acid. 
Fosfomycin had the bestactivity among antibiotics 
used, where strains showed 82% susceptibility. We 
observed high resistance rate tocotrimoxazolewith 
83% (269/324), this is in line with reports of 
BonniCisse et al.[27] and Guessennd et al. [25]in which 
they reported 76% and 91% resistance to 
cotrimoxazole respectively in Ivory Coast. These high 
rates could be attributed to the use of cotrimoxazole 
in chemoprophylaxis in the treatment of 
opportunistic infections in immunocomprimised 
patients.  
The resistance to antibiotics and ESBL production 
spares no country in the world.The frequencies of 
ESBL producing strains vary from country to country 
and from species to species in the world [22, 23].  
Studies carried out by Ouedraogo et al. [24]in Burkina 
Faso. Mohantyet al. [26]in India reported the overall 
prevalence of 58% and 69% ESBL producing bacteria 
respectively. Our study showed a prevalence of 35% 
ESBL producing strain which is relatively high and is 
almost similar to other data which showed high 
prevalence. 
 This resistance is often associated with antibiotics 
such as aminoglycosides and quinolones (Table 2). 
The emergence of these Bacteria Multi-Resistances 
(BMRs) in hospitals of Ouagadougou could lead to 
therapeutic failures despite the administration of 
aminoglycosidesand 3rd generation cephalosporins. 
While the issue of antibiotic resistance has long been 
considered a concern in hospitals for nosocomial 
infections, in recent years the problem has been 
extended to include community medicine [32]. One of 
the reasons is the high consumption of antibiotics in 
human medicine, the illicit sale of antibiotics on the 
streets, and the increased movement of colonized or 
infected patients between hospitals and community 
settings [32]. 
However, the good susceptibility of the ESBL-
producingEnterobacteriaceae to imipenem100% 
(114/114) and also to amikacin93% (106/114), 
cefoxitin74% (84/114) and fosfomycin84% (96/114) 
makes them the molecules of choice in alone 
treatment or in combination of other antibiotics (Table 
2). 
These results should act as an impetus for the 
establishment of antibiotic control policies. Indeed, 
currently there is no restriction in the use of 
antibiotics in Burkina Faso. 
 
Conclusion 
UTIs antibiotics therapyshould be guided by 
antimicrobial susceptibility as increasing numbers of 
urinary isolates are developing resistance to 
commonly use antibiotics. Increasing antimicrobial 
resistance of Enterobacteriaceae has led to 
reconsideration of traditional treatment of 
recommendations in many areas. This experimental 
study should be followed by several studies on 
antimicrobial resistance among patients in Burkina 
Faso hospitals and other regions of West Africa as 
there is relatively few data concerning the antibiotic 
susceptibility spectrum of bacteria isolated from 
patients with UTIs. 
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